Repros shares skyrocket on promising testosterone data

Repros Therapeutics got a badly needed lift this morning after it announced that a small study of Androxal demonstrated its ability to restore sperm count and boost testosterone levels in men with secondary hypogonadism. Investors nearly tripled the value of its batter shares, which had been mauled as the company was forced to scramble for cash as it experienced problems with its lead drug Proellex.

The small study compared Androxal to Auxilium Pharmaceuticals' Testim. "Androxal may fill the need for a drug that is able to restore testicular function and at the same time provide the benefits that normalization of testosterone provides to hypogonadal men," said Dr. Jed Kaminetsky, the lead investigator. "If Androxal can be safely developed, it will represent an important new treatment option for men with secondary hypogonadism with a continued fertility interest."

In a statement, the company said that it would determine if the FDA found its "observations to be clinically relevant and whether a development program can be designed to confirm the findings of this exploratory study, and ultimately support a label for the treatment of secondary hypogonadism in men who wish to preserve their fertility."

- check out the Repros release
- here's the Reuters story

Related Articles:
FDA expresses doubt about Repros' Proellex
Repros suspends trial, hunts for funding
Repros drops top dose for late-stage study